+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Matrix metalloproteinases and atherosclerotic plaque instability

Matrix metalloproteinases and atherosclerotic plaque instability

British Journal of Surgery 89(6): 680-694

There is growing interest in the role of matrix metalloproteinases in atherosclerosis. Excessive tissue remodelling and increased matrix metalloproteinase activity have been demonstrated during atherosclerotic plaque disruption, a frequent predeterminant of ischaemic cardiac events and stroke. These enzymes represent a potential target for therapeutic intervention to modify vascular pathology. The core of this review is derived from a Medline database literature search. There is convincing evidence of increased matrix metalloproteinase activity during acute plaque disruption. Evidence for an imbalance promoting increased matrix degradation is less well documented. However, studies of matrix metalloproteinase inhibition in models of vascular disease suggest a potential therapeutic benefit. In vivo studies of matrix metalloproteinase inhibition are required to study the potential for reversal or deceleration of the excessive tissue remodelling that accompanies acute plaque disruption.

(PDF emailed within 0-6 h: $19.90)

Accession: 046631310

Download citation: RISBibTeXText

PMID: 12027977

DOI: 10.1046/j.1365-2168.2002.02099.x

Related references

Elastinolytic matrix metalloproteinases and their inhibitors as therapeutic targets in atherosclerotic plaque instability. Cardiology in Review 12(3): 141-150, 2004

Matrix metalloproteinases-9 and -12 have opposite effects on atherosclerotic plaque stability. European Heart Journal 24(Abstract Suppl.): 118, August-September, 2003

A fluorescence lifetime spectroscopy study of matrix metalloproteinases-2 and -9 in human atherosclerotic plaque. Journal of Biophotonics 4(9): 650-658, 2011

Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Review of Cardiovascular Therapy 5(2): 265-282, 2007

Carotid artery plaque instability is associated with expression of matrix metalloproteinases 2 and 12. British Journal of Surgery 87(4): 490-0, 2000

Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiological Reviews 85(1): 1-31, 2004

Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proceedings of the National Academy of Sciences of the United States of America 102(43): 15575-15580, 2005

Angiotensin II mediates production of matrix metalloproteinases-1 and -9 by monocytes Implication for atherosclerotic plaque rupture. Circulation 106(19 Suppl.): II-43, November 5, 2002

Genetic strategies to elucidate the roles of matrix metalloproteinases in atherosclerotic plaque growth and stability. Circulation Research 97(10): 958-960, 2005

Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. Journal of Clinical Neurology 7(2): 69-76, 2011

Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability. Journal of Vascular Research 53(1-2): 1-16, 2016

Presence of CD40 and CD40L in human atherosclerotic plaque Implications for matrix metalloproteinases expression by endothelial cells. European Heart Journal 18(ABSTR SUPPL ): 228, 1997

Specific matrix metalloproteinases play different roles in intraplaque angiogenesis and plaque instability in rabbits. Plos One 9(9): E107851, 2015

Inhibiting extracellular matrix metalloproteinase inducer maybe beneficial for diminishing the atherosclerotic plaque instability. Journal of Postgraduate Medicine 55(4): 284-286, 2010

Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability. Nuclear Medicine and Biology 41(7): 562-569, 2015